The advent of technologies to express heterologous proteins in planta has led to the proposition that plants may be engineered to be safe, inexpensive vehicles for the production of vaccines and possibly even vectors for their delivery. The immunogenicity of a variety of antigens of relevance to vaccination expressed in different plants has been assessed. The purpose of this article is to examine the utility of plant-expression systems in vaccine development from an immunological perspective.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (2000) Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des 6:261–276
CDC (2002) General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Mort Morbid Wkly Rep 51(RR02):1–36
Choe NW, Estes MK, Langridge WH (2006) Synthesis of a ricin toxin B subunit-rotavirus VP7 fusion protein in potato. Mol Biotechnol 32:117–128
Choi NW, Esters MK, Langridge WH (2006) Ricin Toxin B subunit enhancement of rotavirus NSP4 immunogenicity in mice. Viral Immunol 19:54–63
Cohen-Kaminsky S, Jambou F (2005) Prospects for a T-cell receptor vaccination against myasthe-nia gravis. Expert Rev Vaccines 4:473–492
Cui Z, Qiu F (2006) Synthetic double-stranded RNA poly (I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 55:1267–1279
Diebold SS, Plank C, Cotton M, Wagner E, Zenke M (2002) Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet 27:65–74
Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914–4919
Faria AM, Weiner HL (2005) Oral tolerance. Immunol Rev 206:232–259
Fujihashi K, Koga T, van Ginkel FW, Hagiware Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20:2431–2438
Gleba Y, Klimyuk V, Marillonnet S (2005) Magnification-a new platform for expressing recom-binant vaccines in plants. Vaccine 23:2042–2048
Gustafson GL, Rhodes MJ (1992) Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol 143:483–488
Hanlon CA, DeMattos CA, DeMattos CC, Niezgoda M, Hooper DC, Koprowski H, Notkins A, Rupprecht CE (2001) Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19:3834–3842
Helm RM, Furuta GT, Stanley JS, Ye J, Cockrell G, Connaughton C, Simpson P, Bannon GA, Burks AW (2002) A neonatal swine model for peanut allergy. J Allergy Clin Immunol 109:136–142
Jalava K, Eko FO, Riedmann E, Lubitz W (2003) Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines 2:45–51
Jenner E (1798) An inquiry into the causes and effects of the variolae vaccine. London: printed for the author by Sampson Law
Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614
Ko K, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S, Hanlon CA, Rupprecht C, Dietzschold B, Golovkin M, Koprowski H (2003) Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A 100:8013–8018
Ko K, Steplewski Z, Glogowska M, Koprowski H (2005) Inhibition of tumor growth by plantderived mAb. Proc Natl Acad Sci U S A 102:7026–7030
Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760
Kumpel BM (2002) On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 82:67–73
Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R, Cox J, Luft T, Gardner J, Suhrbier A (2004) ISCOM based vaccines for cancer immunotherapy. Vaccine 22:963–974
Li ZG, Mu R, Dai ZP, Gao XM (2005) T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 14:884–889
Lyche N (2005) Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 5:591–597
Pasteur L (2002) Summary report of the experiments conducted at Pouilly-le-Fort Near Melun, on the anthrax vaccination. Classics of Biology and Medicine. Yale J Biol Med 75:59–62
Ramon G, Zoeller C (1927) L'anatoxine tétanique et l'immunisation active de l'homme vis-à -vis du tétanos. Ann Inst Pasteur 41:803–833
Robinson JH, Delvig AA (2002) Diversity in MHC class II antigen presentation. Immunology 105:252–262
Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47:57–77
Schijns VE (2001) Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol 21:75–85
Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516–521
Vandenbark AA, Morgan E, Bartholomew R, Bourdette D, Whitham R, Carlo D, Gold D, Hashim G, Offner H (2001) TCR peptide therapy in human autoimmune diseases. Neurochem Res 26:713–730
Verch T, Yusibov V, Koprowski H (1998) Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 220:69–75
Vichier-Guerre S, Lo-Man R, BenMohamed L, Deriaud E, Kovats S, Leclerc C, Bay S (2003) Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anticancer vaccine for human use. J Pept Res 62:117–124
Weinstein PD, Cebra JJ (1991) The preference for switching to IgA expression by Peyer's patch germinal center B cells is likely due to the intrinsic influence of their microenvironment. J Immunol 147:4126–4135
Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155–3164
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hooper, D.C. (2009). Plant Vaccines: An Immunological Perspective. In: Karasev, A.V. (eds) Plant-produced Microbial Vaccines. Current Topics in Microbiology and Immunology, vol 332. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70868-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-540-70868-1_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-70857-5
Online ISBN: 978-3-540-70868-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)